Vaxcyte (PCVX) has scheduled a webcast and conference call for March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. The study evaluates the safety, tolerability, and immunogenicity of VAX-24, their 24-valent pneumococcal conjugate vaccine candidate, compared to Prevnar 20® in healthy infants.
VAX-24 is designed to prevent invasive pneumococcal disease (IPD). The presentation will be accessible via phone (800-445-7795 domestic, 785-424-1699 international) with conference ID PCVX0331, and through a live webcast on Vaxcyte's investor relations website. The webcast recording will remain available for 30 days after the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.